Experimental spinal cord therapy sparks controversy in Brazilian courts.

A novel therapy for spinal cord damage is causing a stir in Brazilian courts, attracting patients from distant locations such as Mexico to a modest research facility, prompting the government to speed up the licensing process and catapulting a scientist to fame nationwide ahead of any conclusive clinical trial results.

Polylaminin, a protein derived from placentas, is generating significant interest globally, with numerous individuals seeking access to this potentially revolutionary treatment for nerve regeneration.

Experts warn that without concrete evidence of its benefits and risks, the treatment should be approached with skepticism.

Research conducted on animals since the year 2000 indicates that polylaminin may promote nerve fiber repair.

Public fascination with polylaminin surged following a 2024 preprint of a study, which was heavily promoted by Cristalia, the Brazilian pharmaceutical firm behind the patent, even as Phase 1 trials continue to progress.

Brazilian scientist Tatiana Sampaio, the lead researcher on the project, revealed that a comprehensive study on polylaminin is nearing publication in a respected academic journal.

In Brazil, reactions to Sampaio's treatment have been widespread, with even well-known musicians like Joao Gomes weighing in publicly, as seen during a recent Carnival celebration.

Brazil's national pride is fueled by this latest development.

The researcher's achievement has far-reaching implications worldwide, according to Dr. Sampaio, who identifies as Brazilian.

A breakthrough with polylaminin could bring significant benefits to Brazil's pharmaceutical sector, which has traditionally focused on generic medications, despite the country allocating only 1.2% of its GDP towards R&D, as indicated by the 2023 World Bank statistics.

President Luiz Inacio Lula da Silva's administration is capitalizing on the positive sentiment as it seeks to retain power in upcoming elections.

The Innovation Committee at Anvisa prioritized this product in its inaugural analysis, according to Health Minister Alexandre Padilha. A successful clinical study would enable swift availability for the general public, he noted.

Caution is advised as scientific evidence may not yet validate optimism.

Christopher & Dana Reeve Foundation's chief science officer Marco Baptista describes polylaminin as an innovative and promising treatment, although he acknowledges its status as a relatively untested experimental therapy.

The foundation's founder, a renowned actor known for his iconic Superman role, established it following a devastating 1995 equestrian accident that left him wheelchair-bound.

Baptista emphasized that this method isn't the sole solution, necessitating further evaluation of its safety and effectiveness.

Brazil's top scientists are warning against premature optimism.

Delson Jose da Silva, president of the Brazilian Academy of Neurology, emphasized that success hinges on meeting specific requirements for the research project.

Eight individuals with complete spinal cord damage participated in the initial polylaminin trial, divided equally between those paralyzed from the waist down and those paralyzed entirely.

Six individuals survived the ordeal, but unfortunately, two lost their lives as a result of their severe injuries. One remarkable case involved a person with a broken neck, who regained complete mobility within two years following treatment.

Bruno Drummond de Freitas's remarkable progress can be attributed in part to the presence of polylaminin during his treatment.

A vocal advocate for the therapy has emerged in Freitas, now 23 years old, after receiving polylaminin just 24 hours post-injury.

Overenthusiasm surrounding the treatment's potential may ultimately result in unmet expectations.

In the aftermath of a severe motocross injury in early December, Luiz Fernando Mozer, an auto painter aged 38, underwent experimental spinal cord therapy, but its effects were limited to restoring feeling in his lower limbs.

His prolonged rehabilitation process is causing growing frustration and disappointment every day now. Frustration mounts as expected outcomes fail to materialize slowly.

Patients in Brazil can now navigate their country's complex legal framework to gain access to untested medical treatments via court proceedings. According to Anvisa, numerous cases have been initiated since the experimental treatment gained widespread attention.

Desperate patients may be vulnerable to exploitation due to the high-profile nature of these cases. According to health law specialist Vanessa Patricia, some lawyers have taken advantage of chronic patients by charging them for treatments they're not entitled to receive.

Research indicates that optimal treatment with polylaminin occurs when administered within a 72-hour window post-injury, also effective for up to three months afterwards.

Patients are seeking legal advice due to Anvisa's lengthy review process, which can last up to 45 days.

Patricia noted that Anvisa is now expediting approval processes when a treatment's efficacy is evident, thus reducing the need for judicial involvement.

As of now, a total of 84 patients have been granted permission by Anvisa to utilize polylaminin on a compassionate basis.

The cost of legal representation for individuals fighting for access to polylaminin therapy can be substantial, ranging between 15,000 and 300,000 reais.

With an increasing number of complex cases emerging, Sampaio has found it challenging to personally oversee every aspect, particularly those involving 24-hour legal injunctions that necessitate immediate treatment before thorough assessment can be conducted by researchers. Her dedication to the project remains unwavering despite these logistical hurdles.

Cristalia's Vice President for Research and Innovation, Rogerio Almeida, announced that the company will provide the medication to acute patients after receiving regulatory approval from Anvisa.

Sao Paulo's countryside is home to Cristalia, which has allocated a substantial sum for polylaminin development: 110 million reais.

A clinical trial, cleared by Anvisa, will evaluate the safety of polylaminin in a group of five individuals, ranging from 18 to 72 years old, who received treatment within 72 hours of suffering severe thoracic spinal cord injuries necessitating surgical intervention.

A non-profit advocate for evidence-based policymaking, Natalia Pasternak, expressed concern that publicly available records fail to justify Anvisa's approval of the trial. She has taken her inquiry to a Brazilian court.

Conducting thorough clinical trials with a well-established protocol requires patience, as shortcuts can jeopardize the integrity of results.